888327-28-4

Basic information

• Product Name: methyl 4-amino-2,3-dihydro-1H-indene-2-carboxylate
• Synonyms: methyl 4-amino-2,3-dihydro-1H-indene-2-carboxylate;Methyl 4-amino-1,3-dihydro-2H-indene-2-carboxylate;Methyl 4-aminoindane-2-carboxylate;1H-Indene-2-carboxylicacid, 4-amino-2,3-dihydro-, methyl ester;rac-Methyl 4-amino-2,3-dihydro-1H-indene-2-carboxylate
• CAS NO: 888327-28-4
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.23
• Mol File: 888327-28-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 322℃
• Flash Point: 173℃
• Appearance: /
• Density: 1.207
• PKA: 4.24±0.40(Predicted)
• CAS DataBase Reference: methyl 4-amino-2,3-dihydro-1H-indene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-amino-2,3-dihydro-1H-indene-2-carboxylate(888327-28-4)
• EPA Substance Registry System: methyl 4-amino-2,3-dihydro-1H-indene-2-carboxylate(888327-28-4)

Safety Data

• Hazardous Substances Data: 888327-28-4(Hazardous Substances Data)

Usage

General Description

Methyl 4-amino-2,3-dihydro-1H-indene-2-carboxylate is a chemical compound with the molecular formula C12H13NO2. It is a carboxylate ester that contains an amino group and a dihydroindene ring. methyl 4-amino-2,3-dihydro-1H-indene-2-carboxylate has potential biological activity and may be used in the synthesis of other organic compounds. It can also be used as a building block for the development of pharmaceuticals and agrochemicals. Additionally, it may have applications in the field of organic synthesis and chemical research. Overall, methyl 4-amino-2,3-dihydro-1H-indene-2-carboxylate is a versatile compound with various potential uses in the chemical and pharmaceutical industries.

Upstream product

• 888327-27-3 methyl 4-nitro-2,3-dihydro-1H-indene-2-carboxylate 
• 209225-00-3 4-nitro-2,3-dihydro-1H-indene-2-carboxylic acid 
• 888327-26-2 dimethyl 4-nitro-1,3-dihydro-2H-indene-2,2-dicarboxylate 
• 66126-16-7 1,2-bis(bromomethyl)-3-nitrobenzene 
• 83-41-0 2,3-dimethylnitrobenzene 

Downstream Products

• 1191414-10-4 methyl 4-({[4-(bromomethyl)phenyl](cyclopentyl)acetyl}amino)-2,3-dihydro-1H-indene-2-carboxylate 
• 888326-81-6 4-[3-(4-trifluoromethoxy-phenyl)-3,9-diaza-bicyclo[3.3.1]nonane-9-sulfonyl]-indan-2-carboxylic acid 
• 888327-48-8 4-[3-(4-trifluoromethoxy-phenyl)-3,9-diaza-bicyclo[3.3.1]nonane-9-sulfonyl]-indan-2-carboxylic acid methyl ester 

Relevant articles and documents

Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)

Herein we describe the discovery, mode of action, and preclinical characterization of the soluble guanylate cyclase (sGC) activator runcaciguat. The sGC enzyme, via the formation of cyclic guanosine monophoshphate, is a key regulator of body and tissue homeostasis. sGC activators with their unique mode of action are activating the oxidized and heme-free and therefore NO-unresponsive form of sGC, which is formed under oxidative stress. The first generation of sGC activators like cinaciguat or ataciguat exhibited limitations and were discontinued. We overcame limitations of first-generation sGC activators and identified a new chemical class via high-throughput screening. The investigation of the structure-activity relationship allowed to improve potency and multiple solubility, permeability, metabolism, and drug-drug interactions parameters. This program resulted in the discovery of the oral sGC activator runcaciguat (compound 45, BAY 1101042). Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy.

SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS

Disclosed herein are new methods of treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver in a subject by modulating PPARδ with sulfonyl-substituted bicyclic compounds and co

Salts of Modulators Of PPAR and Methods of Treating Metabolic Disorders

Salt forms of potent modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.